ICAM1 and lung carcinoma: Additional studies have shown that ICAM-1 in the systemic circulation of lung cancer patients can bind to leukocyte-function associated antigen-1 of cytotoxic lymphocytes in the blood, enabling cancer cells to evade immune recognition mechanisms (Kim et al., 2017).